Brian Cheng
Stock Analyst at JP Morgan
(1.12)
# 3,603
Out of 4,876 analysts
65
Total ratings
35.85%
Success rate
-17.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Downgrades: Neutral | $130 → $129 | $128.11 | +0.69% | 3 | Jun 2, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $15 → $8 | $9.96 | -19.68% | 4 | May 13, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $41 | $25.96 | +57.94% | 1 | May 2, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $39.05 | - | 1 | Mar 27, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $55.69 | +2.35% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $9.56 | +35.98% | 4 | Feb 28, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $4.19 | - | 2 | Jan 30, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $2.28 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $12.47 | +44.35% | 2 | Dec 16, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $8.14 | +243.98% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $46 | $16.10 | +185.80% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $3.28 | +906.10% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.46 | +310.96% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $8.76 | +174.13% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.42 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $0.29 | +1,618.21% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.18 | +577.97% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.39 | +31.69% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.39 | +3,515.70% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $2.71 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.63 | +859.08% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.14 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.25 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $13.30 | +539.34% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $9.36 | +124.36% | 1 | Aug 3, 2021 |
Blueprint Medicines
Jun 2, 2025
Downgrades: Neutral
Price Target: $130 → $129
Current: $128.11
Upside: +0.69%
iTeos Therapeutics
May 13, 2025
Downgrades: Neutral
Price Target: $15 → $8
Current: $9.96
Upside: -19.68%
CG Oncology
May 2, 2025
Initiates: Overweight
Price Target: $41
Current: $25.96
Upside: +57.94%
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $39.05
Upside: -
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $55.69
Upside: +2.35%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $9.56
Upside: +35.98%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $4.19
Upside: -
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.28
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $12.47
Upside: +44.35%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $8.14
Upside: +243.98%
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $16.10
Upside: +185.80%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $3.28
Upside: +906.10%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.46
Upside: +310.96%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $8.76
Upside: +174.13%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.42
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $0.29
Upside: +1,618.21%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.18
Upside: +577.97%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.39
Upside: +31.69%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.39
Upside: +3,515.70%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $2.71
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.63
Upside: +859.08%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.14
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.25
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $13.30
Upside: +539.34%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $9.36
Upside: +124.36%